Healius Limited

But this hasn't gone down well at the big end of town.

Healius, one of Australia's biggest pathology companies, has told the stock exchange in May the initial wage increase would add $1.8 million to its labor costs in just one quarter.

The company has warned about collection center closures and the possibility of charging patients out-of-pocket fees for pathology tests.

In fact, Healius went further, describing out-of-pocket fees as the only viable option left to bridge the funding gap.

Now, that warning also reflects broader Medicare funding problems, not just these wage increases.

But Australian Clinical Labs has also reported a $1.8 million earnings impact after the initial increases.

A significant pay rise, but it's also an additional cost for whoever employs them.

And I'd love to know how they do the maths.

Now let's turn to the stocks as chosen by you.

The first five we're gonna take a look at, Healius ... develop, uh, global, uh, well, in fact, sorry, Lovisa there as well, Qantas, and the BetaShares Global Royalties ETF.

So let's, uh, take a look at Healius, the first stock.

Uh, Dorothy's asking about this one.

It's the healthcare company providing, uh, well, medical and those related services such as, uh, lab pathology and imagery services.

Um, has, uh, sold its, uh, clinical research subsidiary, Agilix Biolabs, uh, for around $160 million.

Uh, Andrew, what do you think of Healius at the moment?

Yeah, I mean, Healius was having their moment in the sun during COVID, you know, when we were all getting our jabs and getting tested and, and all that sort of stuff, but, uh, subsequently has been, um, underwhelming.

I'm on the call on OSBIs at noon, so looking forward to that.

Uh, some of the stocks we'll be talking about today include, uh, Healius, Lovisa, Develop Global, Qantas, uh, one ETF Royal, uh, and, uh, Argo, Rio, Sims, Bendigo, and Megaport.

So a nice bunch of stocks to look at today.

Well, that's it.